Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02988960 · ClinicalTrials.gov registry record · Phase 1
A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid Tumors
A Phase 1 study of Advanced Solid Tumors Cancer, sponsored by AbbVie.
- Active
- Registry status
- Phase 1
- Development phase
- 163
- Enrollment target
- 20
- Study locations
NCT02988960 is a Phase 1 study of Advanced Solid Tumors Cancer that is active but no longer recruiting, run by AbbVie. The registered enrollment target is 163 participants, below the 336-participant average among 9 other Advanced Solid Tumors Cancer trials with a reported enrollment target (51% lower). The trial reports 20 study locations across 18 states.
The verdict
NCT02988960, a Phase 1 study of Advanced Solid Tumors Cancer, is active but no longer recruiting, sponsored by AbbVie.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 163 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a dose-escalation study designed to evaluate the safety, pharmacokinetics, and pharmacodynamics of ABBV-927, and to determine the maximum tolerated dose (MTD) or recommended Phase 2 dose (RPTD) for ABBV-927 when administered as monotherapy or as combination therapy with ABBV-181 in participants with advanced solid tumors.
Conditions Studied
Interventions
- DRUG ABBV-927
- DRUG ABBV-181
Study Locations (20)
Victoria
- Peninsula Oncology Centre /ID# 164372 - Frankston
- Austin Health /ID# 171189 - Heidelberg
Other
- Yonsei University Health System Severance Hospital /ID# 166292 - Seoul
- Hospital Universitario Fundacion Jimenez Diaz /ID# 200128 - Madrid
California
- The Angeles Clinic and Researc /ID# 156324 - Los Angeles
Illinois
- The University of Chicago Medical Center /ID# 155264 - Chicago
Massachusetts
- Massachusetts General Hospital /ID# 155267 - Boston
North Carolina
- Carolina BioOncology Institute /ID# 155265 - Huntersville
Tennessee
- Tennessee Oncology-Nashville Centennial /ID# 158654 - Nashville
Texas
- University of Texas MD Anderson Cancer Center /ID# 155263 - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 163 participants |
| Start Date | 2017-02-22 |
| Est. Completion | 2026-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02988960
The ClinicalTrials.gov registry entry for NCT02988960 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 163 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 336-participant average among 9 other Advanced Solid Tumors Cancer trials with a reported enrollment target (51% lower). The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Solid Tumors Cancer appearing as the primary indexed condition, and to 2 interventions - of which ABBV-927 is the first listed.
NCT02988960 reports 20 study locations spanning 18 distinct geographic areas - top geographies include Victoria, Other, California.
Frequently Asked Questions
What is clinical trial NCT02988960 about?
NCT02988960 is a clinical study titled "A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid Tumors". This is a dose-escalation study designed to evaluate the safety, pharmacokinetics, and pharmacodynamics of ABBV-927, and to determine the maximum tolerated dose (MTD) or recommended Phase 2 dose (RPTD) for ABBV-927 when administered as monotherapy or as combination therapy with ABBV-181 in participa...
What is the current status of trial NCT02988960?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 163 participants. The study started on 2017-02-22. Estimated completion is 2026-09.
What conditions does trial NCT02988960 study?
This clinical trial studies the following conditions: Advanced Solid Tumors Cancer.
What interventions are being tested in trial NCT02988960?
The interventions under investigation include: ABBV-927 (DRUG), ABBV-181 (DRUG).
Who is sponsoring clinical trial NCT02988960?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02988960 being conducted?
This trial has 20 study locations across California, Illinois, Massachusetts, North Carolina, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumors Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
PQ203 in Advanced Malignant Tumors Including Triple Negative Breast Cancer
RECRUITING · Phase 1
-
A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors.
RECRUITING · Phase 1
-
ORB-021 In Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
-
Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
-
A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.